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Abstract
In Noonan Syndrome (NS) 30% to 50% of subjects show cognitive deficits of unknown etiology 
and with no known treatment. Here, we report that knock-in mice expressing either of two NS-
associated Ptpn11 mutations show hippocampal-dependent spatial learning impairments and 
deficits in hippocampal long-term potentiation (LTP). In addition, viral overexpression of the 
PTPN11D61G in adult hippocampus results in increased baseline excitatory synaptic function, 
deficits in LTP and spatial learning, which can all be reversed by a MEK inhibitor. Furthermore, 
brief treatment with lovastatin reduces Ras-Erk activation in the brain, and normalizes the LTP 
and learning deficits in adult Ptpn11D61G/+ mice. Our results demonstrate that increased basal Erk 
activity and corresponding baseline increases in excitatory synaptic function are responsible for 
the LTP impairments and, consequently, the learning deficits in mouse models of NS. These data 
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also suggest that lovastatin or MEK inhibitors may be useful for treating the cognitive deficits in 
NS.
Introduction
Noonan syndrome (NS) is an autosomal dominant genetic disorder with an incidence of ~1 
in 2,500 live births characterized by facial abnormalities, short stature, motor delay and 
cardiac defects1, 2. Importantly, 30% to 50% of NS patients show cognitive deficits3–6. NS 
patients also show clumsiness, motor delay, hearing loss, deficits in spatial knowledge, 
planning, and social/emotional problems3, 4, 7. Recent studies showed that NS patients show 
impairments in hippocampal-dependent memory tasks4, 8, 9.
Germ line mutations in genes involved in Ras-Erk signaling such as PTPN11, SOS1, KRAS, 
NRAS, RAF1, BRAF, SHOC2, MEK1 and CBL have been reported to cause NS1, 10. Among 
those, mutations in the PTPN11 gene, which encodes the non-receptor protein tyrosine 
phosphatase SHP2, account for ~ 50% of NS cases1. SHP2 is a positive regulator for Ras-
Erk signaling11 which is critically involved in many cellular processes including learning 
and memory12. The PTPN11 mutations found in NS patients result in gain-of-function 
alleles that up-regulate this signaling cascade11, 13–15. Cognitive problems, such as learning 
disabilities and memory impairments, are common in NS3, 5, 6. However, little is known 
about the role of PTPN11 in synaptic plasticity and learning and memory in the mammalian 
brain. Furthermore, there is no available treatment for cognitive deficits associated with this 
common genetic disorder.
Previous studies, that used NS mouse models derived by knocking-in mutations in the NS-
associated Ptpn11 gene, demonstrated that the heterozygous knock-in mice show 
phenotypes similar to those found in NS patients. These include short stature, craniofacial 
abnormalities, myeloproliferative disease and multiple cardiac defects14, 16. In the present 
study, we first tested whether NS mutant mice have deficits in learning and memory and 
synaptic plasticity. Then, we asked whether increasing SHP2 activity in adult brain affects 
synaptic function, LTP and learning and memory. Finally, we examined whether it is 
possible to rescue the LTP and learning deficits of NS mutant mice in adults.
Results
NS mutant mice show deficits in spatial learning and memory
To investigate the underlying mechanism of the learning and memory deficits associated 
with NS, we studied two lines of heterozygous knock-in mice harboring gain-of-function 
mutations found in NS patients14, 16: Ptpn11D61G/+ and Ptpn11N308D/+. Previous studies 
showed that the Ptpn11D61G/+ mutation causes more severe phenotypes than the 
Ptpn11N308D/+ mutation14, 16. As NS patients show deficits in spatial function and in 
memory tasks dependent on the hippocampus4, 8, 9, we tested both Ptpn11 mutants in the 
hidden platform-version of the Morris water maze17. In this task, mice learn to use spatial 
cues around a pool to find an escape platform hidden beneath the water surface. Following 
training, memory is assessed in probe trials wherein the mice search for 60 seconds with the 
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platform removed from the pool. Ptpn11N308D/+ mutants showed comparable latencies to 
find the hidden platform to their wild-type (WT) controls during training (Fig. 1a; Repeated 
measures ANOVA, F1, 18 = 2.078, P = 0.167) and showed normal swimming speeds in 
probe trials (WT, 17.33 ± 1.55 cm/s, n = 11 mice; Ptpn11N308D/+, 18.37 ± 0.82 cm/s, n = 9 
mice; unpaired two-tailed t-test, t = 0.554, P = 0.586). However, in probe trials 
Ptpn11N308D/+ mutants spent significantly less time than WT mice in the target quadrant 
where the platform was located during training (Fig. 1b; WT, 57.87 ± 4.83 %; 
Ptpn11N308D/+, 41.85 ± 4.30 %; unpaired two-tailed t-test, t = 2.421, * P < 0.05). Also, the 
searches of WT mice during the probe trials were closer to the target platform than those of 
the mutants (WT, 32.53 ± 2.26 cm; Ptpn11N308D/+, 40.18 ± 2.05 cm; unpaired two-tailed t-
test, t = 2.450, * P < 0.05). In contrast, Ptpn11N308D/+ mutants performed normally in the 
visible-platform version of the water maze (Supplementary Fig. 1), suggesting that the 
Ptpn11N308D/+ mutation does not impair either visuomotor function or motivation. After 
extended training, the Ptpn11N308D/+ mutants reached a level of performance comparable to 
WT mice in probe trials, demonstrating that they can acquire spatial information, albeit at a 
slower rate than WT mice (Supplementary Fig. 2). In addition, Ptpn11N308D/+ mutants also 
showed deficits in contextual fear conditioning, another hippocampus-dependent task 
(Supplementary Fig. 3).
In agreement with the greater severity of phenotypes associated with the D61G mutation 
compared with the N308D mutation in both mutant mice and NS subjects6, 15, 16, 18, 
Ptpn11D61G/+ mice showed a more severe behavioral phenotype than Ptpn11N308D/+ mice. 
In probe trials, Ptpn11D61G/+ mice did not search selectively in the target quadrant (Fig. 1d; 
F3,36 = 2.029, P = 0.127 and F3,56 = 23.51, *** P < 0.0001 for Ptpn11D61G/+ and WT, 
respectively; one-way ANOVA) and spent more time searching further from the former 
platform location than did WT littermates (WT, 46.23 ± 1.29 cm, n = 15 mice; 
Ptpn11D61G/+, 52.43 ± 2.14 cm, n = 10 mice; unpaired two-tailed t-test, t = 3.178, * P < 
0.05). Even with additional training, Ptpn11D61G/+ mice were unable to reach WT 
performance levels (Supplementary Fig. 2). Furthermore, Ptpn11D61G/+ mice took longer to 
reach the platform during training for both the hidden (Fig. 1c; Repeated measures ANOVA, 
F1, 23 = 38.54, *** P < 0.0001) and the visible-platform versions (Supplementary Fig. 1) of 
the Morris water maze, and showed slower swimming speeds (Ptpn11D61G/+, 11.98 ± 1.27 
cm/s, n = 10; WT, 19.72 ± 0.46 cm/s, n = 15; unpaired two-tailed t-test, t = 6.618, *** P < 
0.0001), which might have contributed to their longer latencies to reach the platform. 
Additional behavioral characterization in an open field test revealed that Ptpn11D61G/+ mice 
were hypoactive (Supplementary Fig. 1). These data demonstrate that the behavioral deficits 
of Ptpn11D61G/+ mice go beyond spatial learning and memory abnormalities. Importantly, 
the phenotype of NS patients also is not limited to cognitive deficits and can include other 
neurologic abnormalities, such as a higher rates of motor delay, clumsiness and poor 
coordination2.
NS mutant mice show deficits in synaptic plasticity
Hippocampal long-term potentiation (LTP) in the Schaffer collateral synapses of CA1 cells 
has a key role in spatial learning and memory19. To identify the mechanism responsible for 
the learning and memory deficits caused by the Ptpn11 mutations, we examined CA1 
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Schaffer collateral LTP in Ptpn11N308D/+ and Ptpn11D61G/+ mice by performing 
extracellular field recordings in acute hippocampal slices. Ptpn11N308D/+ and WT slices 
showed no significant differences in basal synaptic transmission or paired-pulse facilitation 
(Supplementary Fig. 4). However, LTP induced with theta-burst stimulation (TBS; 2 or 5 
theta bursts) was significantly reduced in Ptpn11N308D/+ mice (Fig. 2a; last 10 min of 
recording, WT, 159.5 ± 4.23 %, n=6 slices from 6 mice; Ptpn11N308D/+, 143.4 ± 4.81 %, 
n=6 slices from 6 mice; unpaired two-tailed t-test, t = 2.506, P < 0.05; Supplementary Fig. 
5). Consistent with the hypothesis that these LTP deficits account for the learning 
impairments in Ptpn11 mutant mice, Ptpn11D61G/+ mice, with the bigger learning 
impairments, also showed more severe LTP deficits than those in Ptpn11N308D/+ mice (Fig. 
2b; last 10 min of recording, WT, 139.2 ± 8.41 %,, n=7 slices from 7 mice; Ptpn11D61G/+, 
110.8 ± 6.30 %, n=7 slices from 6 mice; unpaired two-tailed t-test, t = 2.698, P < 0.05). As 
in Ptpn11N308D/+ mice, basal synaptic transmission and paired-pulse facilitation were 
normal in Ptpn11D61G/+ mutants (Supplementary Fig. 4).
Adult expression of PTPN11D61G impairs LTP and memory
The mutations in Ptpn11 mice are present throughout development, affect the entire body 
and could disrupt the function of brain structures other than the hippocampus. Similarly, NS 
is a systemic developmental disorder, and it has been assumed that developmental defects 
are responsible for the cognitive deficits in these patients20. Viral vectors provide spatial and 
temporal regulation of gene expression critical for testing the specific role of Ptpn11 
mutations in the adult brain. Moreover, NS alleles severely compromise the viability of 
mutant mice14, thus making it very difficult to obtain sufficient number of mutant mice for 
all studies envisioned (Supplementary table 1). To test whether altered Shp2 signaling in the 
adult hippocampus can cause LTP and, consequently, learning deficits, we overexpressed 
mutant PTPN11D61G using recombinant adeno-associated virus (AAV–PTPN11D61G) in the 
CA fields (CA1, CA2 and CA3) of the hippocampus of adult WT mice. PTPN11D61G 
overexpression in the hippocampus (Fig. 3a and Supplementary Fig. 6) resulted in increased 
Erk activation as assessed by immunoblotting p-Erk, confirming that AAV–expressed 
PTPN11D61G is functional (Fig. 3b; n = 5 hippocampi for each group, unpaired two-tailed t-
test, t = 2.452, * P < 0.05). Consistently, AAV–PTPN11D61G expression impaired 
performance in probe trials of the water maze (Fig. 3c). AAV–PTPN11D61G–expressing 
mice spent significantly less time in the target quadrant than did AAV–GFP/vehicle-injected 
control mice (Fig. 3c; PTPN11D61G/veh, 25.89 ± 3.38 %, n=10; GFP/veh, 35.88 ± 2.95 %, 
n=13; unpaired two-tailed t-test, t = 2.231, * P < 0.05). Unlike the Ptpn11D61G/+ mutation in 
mice, AAV–PTPN11D61G expression did not affect swimming speed or other performance 
variables during the acquisition phase of the water maze (Supplementary Fig. 7), suggesting 
that the acute expression of PTPN11D61G in the hippocampus only affects learning and 
memory, whereas deregulation of Shp2–Erk signaling during development in the 
Ptpn11D61G/+ mice might affect other functions including motor coordination. Notably, 
overexpressing WT PTPN11 did not affect basal p-Erk levels or spatial learning and 
memory (Supplementary Fig. 8), demonstrating that the adverse impact on Erk signaling and 
learning and memory is specific to the NS-related PTPN11 mutation.
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AAV–PTPN11D61G–expressing mice were also tested in another hippocampus-dependent 
task (object-place recognition) 24-hours after training; WT AAV–PTPN11–expressing mice 
were used as controls (Fig. 3d). Consistent with the water maze results, PTPN11D61G 
expression in the CA fields of the hippocampus caused memory deficits in this task: the 
control mice spent significantly more time exploring the object at the new location (Fig. 3d; 
n = 15 mice, 59.79 ± 3.72 % for new place, one-sample paired t-test compared to 50 %, t = 
2.633, * P < 0.05), but the PTPN11D61G mice did not (Fig. 3d; n = 15 mice, 52.61 ± 4.10 % 
for new place, one-sample paired t-test compared to 50 %, t = 0.636, P = 0.535). 
Importantly, AAV–PTPN11D61G–expressing mice showed comparable total exploration 
time to that of WT AAV–PTPN11–expressing mice during training (WT AAV–PTPN11, 
43.70 ± 3.98 s, n = 15; AAV–PTPN11D61G, 39.29 ± 4.94 s, n = 15; unpaired t-test, t = 0.695 
P = 0.493). All together, these data show that expressing PTPN11D61G in the adult CA fields 
of the hippocampus is sufficient to disrupt memory, and demonstrate that PTPN11 plays a 
critical role in adult brain function, in addition to its effects on development20.
To test whether reducing Erk activity could reverse the memory deficits in AAV–
PTPN11D61G–expressing mice, we treated these mice with the MEK inhibitor SL327 or 
vehicle daily, 30 min before training. SL327 treatment (32 mg/kg, intraperitoneal injection) 
decreased Erk activation in the hippocampus of control and AAV–PTPN11D61G mice 
(Supplementary Fig. 9). We choose a sub-threshold dose of the drug that does not impair 
spatial learning in WT mice and only decreases hippocampal Erk activation in WT mice by 
~ 25% (Supplementary Fig. 9). Importantly, this SL327 treatment rescued the spatial 
learning deficits of the AAV–PTPN11D61G mice without affecting the performance of the 
AAV–GFP group (Fig. 3c; PTPN11D61G/SL327, one-way ANOVA, F3, 36 = 10.44, P < 
0.001; target vs. other quadrants, Dunnett’s Multiple Comparison Test, * P < 0.05). 
Consistent with the water maze results, the same SL327 treatment also rescued the memory 
deficits in the object-place recognition task (Fig. 3e; WT PTPN11, n = 5, 58.83 ± 2.01 % for 
new place, two-tailed paired t-test compared to 50 %, t = 4.395, * P < 0.05; PTPN11D61G, n 
= 8, 59.90 ± 3.41 % for new place, two-tailed paired t-test compared to 50 %, t = 2.904, * P 
< 0.05). These results demonstrate that increased Ras–Erk signaling in adult CA fields of the 
hippocampus contribute to the memory deficits in AAV–PTPN11D61G–expressing mice. 
Remarkably, SL327 also reversed the memory deficits of the adult Ptpn11D61G/+ mutant 
mice in the Morris water maze, showing that normalizing Erk activity in adults can reverse 
the behavioral deficits even in mutant mice with germ line mutations (Supplementary Fig. 
10).
Next, we asked whether AAV–PTPN11D61G expression in adults also impairs CA1 Schaffer 
collateral LTP. As in Ptpn11D61G/+ mutant mice, hippocampal slices from AAV–
PTPN11D61G–transfected mice showed significantly reduced LTP in response to a TBS 
tetanus (Fig. 3f, g; GFP/veh, 154.8 ± 4.18 %, n = 7 slices from 7 mice; PTPN11D61G/veh, 
131.9 ± 4.38 %, n = 10 slices from 10 mice; unpaired two-tailed t-test, t = 3.625, ** P < 
0.01), demonstrating that manipulating Shp2 signaling specifically in the adult CA fields of 
the hippocampus is sufficient to impair LTP. In addition, TBS failed to further activate Erk 
in AAV–PTPN11D61G-transfected hippocampi (Fig. 3b; n=5 hippocampi for each group, 
unpaired two-tailed t-test, t = 1.580, P = 0.1527). SL327 treatment, which reversed their 
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learning deficits, also normalized CA1 LTP in hippocampal slices from the AAV–
PTPN11D61G-transfected mice (Fig. 3f, g; Two-way ANOVA, F1, 30 = 6.526, * P < 0.05; 
Bonferroni post-test reveals significant effect of SL327 treatment only on the PTPN11D61G 
group, * P < 0.05). It is noteworthy that basal synaptic transmission and paired-pulse 
facilitation were not affected either by AAV–PTPN11D61G expression or by the SL327 
treatment we used (Supplementary Fig. 7). Taken together, these results indicate that 
deregulated Erk activity causes CA1 LTP deficits, and these deficits are responsible for the 
learning and memory impairments in mouse models of NS.
PTPN11D61G overexpression increases excitatory synaptic function
Next, we examined the electrophysiological mechanism underlying the LTP impairment in 
AAV–PTPN11D61G–transfected mice. Increases in Ras signaling are known to facilitate 
AMPA receptor trafficking to the surface membrane21. For example, expression of 
constitutively active Ras enhances AMPA receptor-mediated currents in hippocampal 
neurons and impairs LTP21. Hence, we asked whether the increases in activated Erk 
associated with PTPN11D61G expression enhanced AMPA currents. Whole-cell voltage 
clamp recordings revealed that the ratio of AMPA:NMDA currents was increased in AAV–
PTPN11D61G-transfected hippocampi (Fig. 4a, b; AAV–PTPN11D61G, 1.51 ± 0.11, n = 10 
cells from 5 mice; AAV–GFP, 0.96 ± 0.05, n = 10 cells from 5 mice, unpaired two-tailed t-
test, t = 4.754, *** P < 0.001). Importantly, SL327 treatment normalized the AMPA:NMDA 
ratio (Fig. 4a, b; PTPN11D61G/SL327, 1.07 ± 0.11, n = 7 cells from 6 mice; GFP/SL327, 
1.08 ± 0.07, n = 8 cells from 6 mice; PTPN11D61G/Veh vs. PTPN11D61G/SL327, unpaired 
two-tailed t-test, t = 2.832, * P <0.05). Although paired-pulse facilitation (PPF) ratio was 
unaffected by AAV–PTPN11D61G (Fig. 4c; AAV–PTPN11D61G, n = 12 cells from 5 mice; 
AAV–GFP, n= 11 cells from 5 mice; repeated-measures ANOVA, F1, 21 = 0.010, P = 
0.921), mEPSC frequency (but not amplitude) was enhanced by this manipulation (Fig. 4d; 
GFP/Veh, 1.50 ± 0.53 Hz, n = 9 cells from 3 mice; PTPN11D61G/Veh, 4.64 ± 0.94 Hz, n = 9 
cells from 3 mice; unpaired two-tailed t-test, t = 2.923, ** P < 0.01). The increased 
excitation in PTPN11D61G–transfected mice was reversed by SL327 treatment (Fig. 4d; 
PTPN11D61G/Veh, 4.64 ± 0.94 Hz, n = 9 cells from 3 mice; PTPN11D61G/SL327, 2.02 ± 
0.32 Hz, n = 9 cells from 5 mice; unpaired two-tailed t-test, t = 2.645, * P < 0.05). 
Consistently, mEPSC frequency, but not amplitude, was significantly increased in pyramidal 
neurons of Ptpn11D61G/+ mice compared with WT (Fig. 4e; WT/Veh, 2.68 ± 0.55 Hz, n = 9 
cells from 5 mice; Ptpn11D61G/+/Veh, 5.71 ± 0.56 Hz, n = 10 cells from 3 mice; unpaired 
two-tailed t-test, t = 3.858, ** P < 0.01). Moreover, mIPSC frequency and amplitude were 
unaffected in both AAV–PTPN11D61G-transfected mice and Ptpn11D61G/+ mutants (Fig. 4f; 
mIPSC frequency: GFP, 6.91 ± 0.87 Hz, n = 9 cells from 4 mice; PTPN11D61G, 6.93 ± 1.15 
Hz, n = 7 cells from 4 mice, unpaired two-tailed t-test, t = 0.022, P = 0.983; mIPSC 
amplitude, GFP, 19.13 ± 1.19 pA, n = 9 cells from 4 mice; PTPN11D61G, 20.09 ± 1.62 pA, n 
= 7 cells from 4 mice, unpaired two-tailed t-test, t = 0.486, P = 0.634; Fig. 4g; mIPSC 
frequency: WT, 15.06 ± 2.08, n = 7 cells from 5 mice; Ptpn11D61G/+, 15.35 ± 3.50, n = 8 
cells from 5 mice, unpaired two-tailed t-test, t = 0.0683, P = 0.947; mIPSC amplitude: WT, 
32.91 ± 3.06 pA, n = 7 cells from 5 mice; Ptpn11D61G/+, 33.59 ± 2.32 pA, n = 8 cells from 5 
mice, unpaired two-tailed t-test, t = 0.180, P = 0.860). Importantly, just as with AAV–
PTPN11D61G mice, the increased excitation in Ptpn11D61G/+ mice was reversed by SL327 
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treatment (Fig. 4e; Ptpn11D61G/+/Veh, 5.71 ± 0.56 Hz, n = 10 cells from 3 mice; 
Ptpn11D61G/+/SL327, 2.87 ± 1.02 Hz, n = 9 cells from 3 mice; unpaired two-tailed t-test, t = 
2.508, * P < 0.05), indicating that increased Ras-Erk signaling is responsible for the 
enhanced excitatory synaptic function associated with the Ptpn11D61G mutation.
To test the hypothesis that the increase in excitation caused by the PTPN11D61G mutation is 
due to increases in the number of synapses with AMPA receptors, we transfected cultured 
hippocampal neurons (21 days in vitro, DIV) with PTPN11D61G and labeled surface GluA1 
AMPA receptors (Fig. 5a, b). Indeed, the number of surface GluA1 receptor clusters was 
significantly increased in PTPN11D61G–transfected neurons compared with controls (Fig. 
5a, b; GluA1 particle number per 10 μm: PTPN11D61G, 8.60 ± 0.59, n = 20 neurons, 1,432.6 
μm of dendrites; GFP, 6.76 ± 0.34, n = 22 neurons, 1,759.6 μm of dendrites; unpaired two-
tailed t-test, t = 2.763, ** P < 0.01), a result consistent with the increase in mEPSC 
frequency caused by PTPN11D61G. The size of GluA1 clusters, however, was not affected 
by PTPN11D61G expression (Fig. 5a, b; GluA1 particle size (μm2): PTPN11D61G, 0.19 ± 
0.02, n=20 neurons, 1,432.6 μm of dendrites; GFP, 0.18 ± 0.02, n = 22 neurons, 1,759.6 μm 
of dendrites; unpaired two-tailed t-test, t = 0.319, P = 0.751), a result consistent with the 
finding of normal mEPSC amplitude. To quantitatively analyze the surface expression of 
GluA1, cultured neurons transfected with either WT PTPN11 or PTPN11D61G constructs 
were surface labeled with biotin and the biotinylated surface proteins were pulled-down and 
analyzed (Fig. 5c, d). While the total expression levels of GluA1 were similar in WT 
PTPN11 and PTPN11D61G–expressing neurons, the surface expression of GluA1 was 
significantly increased in PTPN11D61G expressing neurons compared with WT PTPN11–
expressing neurons (Fig. 5c, d; Two-way ANOVA followed by Bonferroni post-test: 
interaction between fraction (total/surface) x virus (PTPN11/PTPN11D61G), F1, 12 = 5.704, * 
P < 0.05; total, PTPN11 vs PTPN11D61G, P > 0.05; surface, PTPN11 vs. PTPN11D61G, * P 
< 0.05). These data support the results from the immunocytochemistry experiments showing 
that PTPN11D61G expression facilitates the surface expression of GluA1. These results 
indicate that post-synaptic changes in AMPA receptor trafficking contribute to the increase 
in excitatory synaptic function caused by the PTPN11D61G mutation.
Lovastatin treatment rescued LTP and learning deficits in Ptpn11D61G/+ mice
A MEK inhibitor SL327 rescued the spatial learning deficits in adult Ptpn11D61G/+ mice 
(Supplementary Fig. 10), suggesting that decreasing basal Erk activation can be a 
therapeutic strategy for learning deficits in NS. Previous studies also showed that lovastatin, 
a blood-brain-barrier-permeable member of a widely used class of FDA–approved drugs 
(statins), decreases the levels of isoprenyl groups required for Ras membrane localization 
and biological activity22, 23. As in AAV–PTPN11D61G–transfected mice, p-Erk levels were 
increased in Ptpn11D61G/+ hippocampi (Fig. 6a; WT/Veh, 100.0 ± 7.23 %, n = 8; 
Ptpn11D61G/+/Veh, 128.2 ± 2.87 %, n = 7; unpaired two-tailed t-test, t = 3.438, * P < 0.05). 
Lovastatin treatment normalized p-Erk levels in mutant hippocampi at concentrations that 
did not affect Erk activation in controls (Fig. 6a; Ptpn11D61G/+/Veh, 128.2 ± 2.87 %, n = 7; 
Ptpn11D61G/+/Lova, 111.8 ± 6.41 %, n = 8; unpaired two-tailed t-test, t = 2.231, * P <0.05). 
Importantly, lovastatin-treated Ptpn11D61G/+ mice showed better performance (e.g., faster 
times to reach the hidden platform of the Morris maze) than vehicle-treated Ptpn11D61G/+ 
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mice (Fig. 6b; Two-way ANOVA followed by Bonferroni post-test, WT/Veh vs. 
Ptpn11D61G/+/Veh, ** P < 0.01, *** P < 0.001; Ptpn11D61G/+/Veh vs. Ptpn11D61G/+/Lova, 
+ P < 0.05) although their swimming speeds were unchanged by the treatment (Fig. 6c; WT/
veh, 18.5 ± 0.6 cm/s, n = 14 mice; Ptpn11D61G/+/veh, 13.6 ± 1.3 cm/s n = 11 mice; WT/
lova, 17.9 ± 0.8 cm/s, n = 13 mice; Ptpn11D61G/+/lova, 14.2 ± 1.1 cm/s, n = 11 mice; two-
way ANOVA with genotype as between-subjects factor and drug treatment as within-
subjects factor, effect of genotype: F1, 45 = 19.79, *** P < 0.0001, interaction: F 1,45 = 
0.4489, P = 0.506). These data suggest that the learning deficits in these animals are not due 
to their slower swimming speeds or other performance deficits. In probe trials, lovastatin-
treated Ptpn11D61G/+ mice, unlike vehicle-treated Ptpn11D61G/+ mice, showed selective 
searching in the target quadrant. Also, during probe trials lovastatin-treated Ptpn11D61G/+ 
mice showed lower average proximity to the platform site (i.e., better performance) than 
vehicle-treated mutant mice, indicating that lovastatin treatment dramatically improved the 
performance of Ptpn11D61G/+ mice in probe trials (Fig. 6d, e; % time spent in target 
quadrant, Ptpn11D61G/+/veh, 33.48 ± 4.44 %, n = 11 mice; Ptpn11D61G/+/Lova, 45.70 ±4.43 
%, n = 11 mice; unpaired two-tailed t-test, t = 1.947, * P < 0.05; proximity to target 
platform, WT/veh, 38.26 ± 2.33 cm, n = 14 mice; WT/Lova, 35.28 ± 3.26 cm, n = 13 mice; 
Ptpn11D61G/+/veh, 49.05 ± 3.15 cm, n = 11 mice; Ptpn11D61G/+/Lova, 39.82 ± 2.53 cm, n = 
11 mice; unpaired two-tailed t-test, WT/veh vs. Ptpn11D61G/+/veh, t = 2.813, ** P < 0.01; 
Ptpn11D61G/+/veh vs. Ptpn11D61G/+/Lova, t = 2.284, * P < 0.05,). Importantly, the spatial 
learning performance of lovastatin–treated Ptpn11D61G/+ mice was indistinguishable from 
controls (Fig. 6d, e). Notably, at the concentration used, lovastatin had no effect on any 
measure of learning in WT animals (Fig. 6d, e).
Consistent with the hypothesis that increased Ras–Erk activity leads to the LTP deficits 
responsible for spatial learning impairment in Ptpn11 mutant mice, the levels of 5 TBS-
induced LTP in lovastatin–treated Ptpn11D61G/+ mice were significantly higher than those in 
the vehicle-treated mutants and indistinguishable from those in WT control animals (Fig. 6f, 
g; two-way ANOVA with genotype as between-subjects factor, F1, 25 = 5.936, * P < 0.05, 
Bonferroni post-test reveals a significant effect of lovastatin treatment only on Ptpn11D61G/+ 
group, ** P < 0.01). By contrast, lovastatin treatment had no effect on LTP in hippocampal 
slices from WT mice (Fig. 6f, g). Thus, lovastatin treatment can normalize LTP deficits and 
spatial learning impairments even in adult Ptpn11D61G/+ mice. Although we cannot exclude 
the possibility that lovastatin may affect other biological processes24, our data suggest that 
lovastatin reverses the spatial learning deficits of Ptpn11D61G/+ mice, by reducing Erk 
activation and consequently correcting LTP deficits.
Discussion
Our study provides compelling evidence that the spatial learning and memory deficits in 
mouse models of NS are caused by enhanced Ras-Erk activation, which disrupts the balance 
between excitation and inhibition (E/I) and impairs hippocampal long-term potentiation. 
Furthermore, our experiments with viral vectors demonstrate that Ptpn11 plays critical roles 
not only in regulating development20, 25, but also in adult brain functions. Consistent with 
our findings, expression of the fly ortholog of SHP2 (Csw) bearing gain-of-function 
mutations impaired long-term memory in Drosophila26.
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In the present study, we used two knock-in mutant mice harboring a D61G or a N308D 
mutation in PTPN11. The D61G mutation is associated with both NS and leukemia and 
shows higher enzymatic activity than N308D, which is only associated with NS15. 
Consistently, Ptpn11D61G/+ mice showed more severe deficits in LTP and learning than 
Ptpn11N308D/+ mice. Although basal-level of p-Erk was significantly higher in the 
hippocampus of Ptpn11D61G/+ mice compared to WT littermates (Fig. 6), we could not 
detect significant increases in basal p-Erk levels in the hippocampus of Ptpn11N308D/+ mice, 
perhaps because these mice showed an overall milder phenotype (Supplementary Fig. 9c).
The activation of Ras-Erk signaling facilitates AMPA receptor trafficking during LTP21 and 
abnormal hyperactivation of postsynaptic Erk signaling impairs hippocampal LTP and 
learning27, 28. Our findings suggest that the PTPN11D61G mutation increases the number of 
synapses with postsynaptic AMPA receptors, thus occluding LTP and therefore impairing 
learning. In agreement with the hypothesis that there are more synapses with AMPA 
receptors, we found that PTPN11D61G expression increases mEPSC frequency, but does not 
affect PPF ratio (Fig. 4c), a form of plasticity very sensitive to changes in pre-synaptic 
function. Additionally, PTPN11D61G expression increased the evoked AMPA:NMDA ratios 
(Fig. 4a, b), another observation consistent with the hypothesis that the PTPN11D61G 
expression resulted in more synapses with AMPA receptors. Importantly, these observations 
were reproduced in both AAV–PTPN11D61G–transfected mice and in the germ line mutants. 
Importantly, PTPN11D61G expression enhanced the surface expression of GluA1 and 
increased the number of surface GluA1 clusters in cultured hippocampal neurons, a finding 
consistent with the hypothesis that the enhancement in excitatory synaptic function driven 
by PTPN11D61G expression is caused by postsynaptic mechanisms. Interestingly, deletion of 
a Ras–Erk regulator (SynGAP) was reported to increase ERK signaling, enhance the levels 
of AMPA receptors, increase mEPSC frequency and impair LTP27.
Deregulation of Ras–Erk signaling has been associated with other genetic disorders 
including neurofibromatosis type I (NF1), Costello syndrome, LEOPARD syndrome, CFC 
syndrome, and Legius syndrome10, 29. Among these, studies with the Nf1+/− mutant mouse, 
which is a model of NF1, demonstrated that increased Ras signaling results in increased 
GABA release (excitation is normal in these mice) that leads to deficits in LTP and, 
consequently, learning and memory impairments30–33. Altogether these findings 
demonstrate that similar behavioral (e.g., spatial learning deficits) and even 
electrophysiological phenotypes (i.e., LTP deficits) can be caused by different cellular 
mechanisms: increases in AMPARs in NS mice and increases in GABA release in NF1 
mice. Homozygous deletion of the NF1 gene in mouse post-natal excitatory neurons does 
not affect either synaptic transmission or learning32, whereas expression of the NS–mutation 
PTPN11D61G in post-natal excitatory neurons does disrupt both synaptic transmission and 
learning, a direct demonstration of the distinct roles of these two Ras signaling modulators.
In this study, we show that postnatal treatment with an FDA–approved drug, lovastatin, can 
reverse learning and memory as well as LTP deficits in an adult NS mouse model. A 
previous study showed that lovastatin treatment can rescue spatial learning problems, 
attention deficits and pre-pulse inhibition deficits in Nf1+/− mutant mice22. Thus, our studies 
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suggest that this FDA–approved drug with a strong safety profile may also be useful for 
treatment of cognitive deficits associated with NS.
ONLINE METHODS
Methods
Mice—Ptpn11D61G/+ mice were backcrossed to 129S6/SvEv and Ptpn11N308D/+ mice were 
backcrossed to C57Bl/6J mice at least 6 times before experiments. Three to six month–old 
male and female mice were used. For AAV experiments, 3 – 4 month-old male C57Bl/6J 
mice (Jackson Laboratory) were used. Mice were randomly assigned to treatment and 
experimental condition. All experiments used littermates as controls and were carried and 
analyzed with the experimenters blinded to genotype and treatment. Animals were group 
housed (2 – 4) on a 12 h light/dark cycle in vivarium at UCLA and CAU. All studies were 
approved by the Animal Research Committee at UCLA and CAU.
Drugs—SL327 (Tocris) was dissolved in DMSO (16 mg/ml) and was injected 
intraperitoneally once daily, 30 min before the water maze experiment at a dose of 32mg/kg. 
The volume of a single injection was under 80 μl. Lovastatin (Mevinolin, Sigma) was 
prepared as previously described22. Briefly, lovastatin was dissolved in ethanol (final 
concentration of 8%) and 1N NaOH was added to convert mevinolin to the sodium salt. The 
pH of the final solution (4 mg/ml) was adjusted to 7.5 with HCl. The Vehicle solution was 
prepared with the same procedure. Lovastatin was administered daily (subcutaneous 
injection, 10 mg/kg) for 3 days before the first training day of the water maze and 6 h before 
training every day thereafter.
AAV—The coding sequence of human PTPN11 with or without the D61G mutation was 
subcloned into the HindIII – NsiI site of the AAV expression vector pSOFF. The resultant 
vector expresses mutant PTPN11 under the synthetic CBA promoter (CMV enhancer and 
chicken beta-actin promoter). Recombinant virus (rAAV5) was purified as previously 
described34. Briefly, an iodixanol gradient purification was performed followed by an ion 
exchange chromatography step which results in a 99 % pure vector preparation as judged by 
silver stained-SDS acrylamide gel fractionation. After the chromatography, the buffer was 
exchanged and the virus was concentrated in Ringer’s solution using a Biomax 100 K 
concentrator (Millipore). Vector titers were determined by Real Time PCR. Typical titers 
were 3.09 × 1012 genome copies/ml. rAAV5-GFP expressing only GFP was used as a 
control. Virus was infused into two sites per hemisphere (1 μl per injection, AP=−2.5, Lat=
+/−2, DV=−1.7; AP=−1.8, Lat=+/−1, DV=−1.6) over 5 min through a 30-gauge Hamilton 
microsyringe. Viruses (GFP, WT PTPN11 or PTPN11D61G) were randomly assigned for 
infusion. After completion of infusion, the syringe was left in place for an additional 5 min. 
All the experiments were done three weeks after the infusion.
Behavior—Behavioral experiments were performed during the light cycle. In the hidden 
platform-version of Morris water maze, mice were trained with two blocks of 2 trials (ITI = 
1min) spaced about 45 min apart. In each training trial, mice were released from a different 
starting position and then were allowed to search for the escape platform for 60 s. The 
platform was submerged 1 cm under the surface of the water. Once a mouse found the 
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platform, it was left there for 15 s. If a mouse did not find the platform within 60 s, it was 
guided to the platform and remained on the platform for 15 s before being removed from the 
pool. Mice were trained for 5 – 7 consecutive days. Memory was assessed in probe trials 
that were given after completion of training as described in the main text. During the probe 
trials, the platform was removed and the mice were allowed to search for it for 60 s. One 
mouse was excluded from further analysis because of floating (no voluntary movement for 
more than 10 s in more than 2 trials). The same group of mice was tested in the visible 
platform–version of Morris water maze. Data were acquired and analyzed using WaterMaze 
software (Actimetrics).
The object-place recognition task included a training and a test session. Before training, 
mice were handled 5 min per day for 4 days, and then habituated in a square box (27.5 cm × 
27.5 cm × 25 cm) for 15 min for another 2 days. One side of the experimental box included 
a prominent cue. During the 10–min training session, mice were placed in the box, exposed 
to two identical objects and allowed to explore these objects. During the test session (24h 
after training), mice were placed back into the experimental box with the same two objects 
for 5 min: one object (Old location) stayed in the same location as during training, while the 
other object (New location) was moved to a new location. For the rescue experiment, SL327 
(32 mg/kg, i.p.) was injected 30 min before the training session. The objects changed during 
the test sessions were randomly counterbalanced between mice. Experiments were 
videotaped and the exploration times were manually analyzed.
Electrophysiology—For extracellular recordings of field excitatory postsynaptic 
potentials (fEPSP), sagittal slices (400 μm) were prepared with a vibratome (VT1000S, 
Leica) in ice-cold artificial cerebrospinal fluid (ACSF). Slices recovered at room 
temperature for at least 90 min before recording in ACSF saturated with 95 % O2 and 5 % 
CO2 containing the following (in mM): 120 NaCl, 3.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.25 
NaH2PO4, 20 NaHCO3 and 10 D-glucose. Recording was performed in a submerged 
chamber perfused with ACSF (32 °C). fEPSPs were recorded with platinum-iridium 
electrodes placed in the CA1 stratum radiatum. Bipolar platinum stimulating electrodes were 
placed in Schaffer collaterals. Baseline responses were measured with stimulation (0.017 
Hz, 0.1 ms pulse duration) at an intensity (typically 20 – 30 μA) that evoked a response that 
was approximately one third of the maximum evoked response. LTP was induced with 
theta-burst stimulation (2 or 5 bursts, each burst consisting of four pulses at 100 Hz with a 
200 ms inter–burst interval). Initial fEPSP slopes were measured and normalized to the 
average of baseline (with Clampfit 10.2).
Whole-cell voltage clamp recordings were done with an Axopatch 200B amplifier (Axon 
Instrument) as previously described31, 32. Coronal slices (350 μm) were prepared in ice-cold 
slice cutting solution containing the following (in mM), 140 2-hydroxy-N,N,N-
trimethylethanaminium chloride (Choline Chloride), 3 Na-Pyruvate, 2.5, KCl, 1 CaCl2, 7 
MgSO4, 26 NaHCO3, 30 D-glucose, 1 kynurenic acid, 1.3 Na-ascorbate. Patch electrodes 
(3–6 MΩ when filled) were filled with a solution containing the following (in mM): 140 Cs-
methanesulfonate, 7 NaCl, 10 HEPES, 0.2 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 5 QX-314. For 
mEPSC recordings, voltage clamp recordings were performed at -60 mV in the presence of 
100 μM picrotoxin and 1 μM TTX. mIPSCs were measured at + 10 mV in the presence of 1 
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mM kynurenic acid and 1 μM TTX. Only recordings during which series resistance changed 
less than 20 % throughout the experiment were analyzed. mPSCs were analyzed with an in-
house analysis software (EVAN)35. For AMPA/NMDA currents ratio experiments, 
recordings were performed in ACSF containing 100 μM picrotoxin. Pyramidal neurons in 
CA1 were voltage-clamped at − 65 mV, and AMPA–mediated EPSCs were evoked by 
stimulating with a bipolar platinum stimulating electrode at 0.1 Hz. After recording 15 
responses, the holding potential was manually changed to + 40 mV to record NMDA 
receptor–mediated EPSCs. The AMPA/NMDA ratio was calculated by dividing the mean 
value of 15 AMPA–mediated EPSC peak amplitudes by the mean value of 15 NMDA 
receptor-mediated EPSC amplitudes measured at 50 ms after the onset of stimulation 
(Clampfit 10.2).
Western blot and immunohistochemistry—Dissected hippocampi were homogenized 
in protein lysis buffer (10mM Tris-Cl pH 6.8, 1.6 % SDS) containing protease and 
phosphatase inhibitor cocktails (Sigma). Supernatants were collected after centrifugation 
and the protein concentration was determined using a BCA assay kit (Thermo). Equal 
amounts of proteins (5 μg) were separated by electrophoresis on a 4 % – 12 % SDS–PAGE 
(Invitrogen), and then transferred to nitrocellulose membranes. After blocking with 5% BSA 
in TBS-T (Tris–buffer saline containing 0.1% Tween-20) for 1 hr at room temperature, 
membranes were hybridized with a primary antibody overnight at 4°C. After washing with 
TBS–T, membranes were incubated with a secondary antibody in 5% non-fat milk/TBS–T 
for 1 hr at room temperature. Signals were visualized by ECL (Thermo) and exposure time 
was adjusted so that the signals measured were in a linear range. After detecting phospho-
Erk, the membranes were stripped and re-probed with a total Erk antibody. The total Erk 
levels were used to normalize each sample. The following primary antibodies were used: 
anti-phospho-Erk (#9101S, Cell Signaling, 1:6000), anti-total Erk (#9102S, Cell Signaling, 
1:5000) and anti-SHP2 (sc-280, Santa Cruz, 1:3000).
For immunohistochemistry of SHP2, rAAV5-PTPN11D61G– or rAAV5–GFP–injected mice 
were perfused with ice-cold 4 % paraformaldehyde and the brains were removed, followed 
by post-fixation in 4 % paraformaldehyde overnight at 4 °C. Coronal brain sections (30 μm 
thick) were mounted onto slide glasses and were treated with 0.3 % H2O2 in methanol for 30 
min to quench endogenous peroxidase activity. After blocking with 5 % normal goat serum 
in TBS–T (0.1 % Triton X–100), sections were incubated with anti-SHP2 antibody (1:100; 
Sc-280, Santa Cruz Biotechnology) for 48 hrs at 4°C. A biotinylated anti-rabbit antibody 
(1:50, 1 h at room temperature; Vector laboratories) was used as a secondary, which was 
followed by avidin-biotin-peroxidase complex (Vector Laboratories) formation for 30 min. 
Signals were visualized by incubating sections in DAB substrate solution (Vector 
Laboratories). For fluorescent immunohistochemistry of SHP2 and Gad67, anti-SHP2 
antibody (1:100, Santa Cruz Biotechnology) and anti-Gad67 antibody (1:500, Millipore, 
MAB5406) were used as primary antibodies, anti-rabbit Alexa-568 (1:250) and anti-mouse 
Alexa-647 (1:250) were used as secondary antibodies. Images were acquired by using a 
confocal microscope (Olympus).
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Sindbis viral vector construction and immunocytochemistry—The coding 
sequence of human PTPN11 with or without the D61G mutation was subcloned into a 
Sindbis viral expression vector (pSinRep5; Invitrogen) and GFP was inserted into the 3′ 
region of the coding sequence along with an additional subgenomic promoter for bicistronic 
expression. Sindbis viruses were produced according to the manufacturer’s protocol 
(Invitrogen) and directly added to the medium of cultured rat hippocampal neurons (DIV21). 
Twelve hours after infection, immunocytochemistry was performed with or without 
permeabilization by using anti-GluA1-N (#AGC-004, Alomone labs) antibody and Cy3–
conjugated anti-rabbit IgG antibody (Jackson ImmunoResearch Lab). Images were acquired 
by using confocal microscope (Zeiss LSM 710) and analyzed by using ImageJ (ver. 1.42q).
Biotinylation of surface proteins—Rat cortical neurons (16–18 DIV) were transfected 
with the Sindbis virus encoding wild type or mutant (D61G) PTPN11 and allowed to be 
expressed for 12 h. The cultures were incubated with sulfo-NHS-SS-biotin (1 mg/ml, 
Thermo Scientific) in ice–cold PBS for 30 min at 4°C, followed by a 10 min incubation in 
ice-cold Tris buffer (100 mM, pH 8.0), and subsequently lysed with a lysis buffer [50 mM 
Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 % Triton X-100, 0.1 % Sodium 
deoxycholate, 1X protease inhibitor (Roche)]. Biotinylated surface proteins were 
precipitated with Streptavidin agarose (Thermo Scientific) through overnight incubation. 
The precipitated beads were washed and used in Western blotting analysis. Antibodies were 
as follows: anti-GluA1-N (1:1000, Alomone labs), anti-Rab4 (1:2000, #6100889, BD 
Transduction Laboratories), anti-Cadherine (1:4000, sc-59876, Santa Cruz Biotechnology), 
anti-β-Actin (1:4000, A5316, Sigma-Aldrich), anti-SHP2 (1:2000, Santa Cruz 
Biotechnology).
Statistics—For water maze data, we used ANOVAs to analyze quadrant occupancy (% 
time spent in quadrant). After initial ANOVA analyses, searching specificity for each 
genotype was determined by comparing target quadrant to other quadrants using Dunnett’s 
Multiple Comparison Test. We also used two-way ANOVAs to analyze the interaction 
between genotypes and pool quadrants. In addition, we compared target quadrant occupancy 
among different groups by using the unpaired two-tailed t-test. Proximity measures between 
two genotypes also were analyzed by the unpaired two-tailed t-test. Effects of drug 
treatments on different genotypes were analyzed by using two-way ANOVA followed by 
appropriate post-hoc tests. LTP data were analyzed by using repeated-measures ANOVA 
followed by Bonferroni test on the responses after LTP induction and unpaired two-tailed t-
test on the average of the last 10 min of recording. For other experiments, we used Student’s 
t-test to compare two groups and ANOVA to compare three or more groups. We did not use 
statistical methods to predetermine the sample sizes, but our sample sizes are similar to 
those reported in previously published papers31–33. Data distribution was assumed to be 
normal but this was not formally tested. All the data are represented as mean ± s.e.m.
A supplementary methods checklist is available.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Lee et al. Page 13
Nat Neurosci. Author manuscript; available in PMC 2016 January 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Acknowledgments
The authors would like to thank Dr. Istvan Mody, Dr. Thomas O’Dell, Dr. Peyman Golshani and Silva lab members 
for their comments on the manuscript and for valuable discussions, Ryan Jones and Dr. Yu Zhou for helping with 
electrophysiological analysis, Dr. Denise Y. Cai for statistical advice, Aida Amin, Hwang Shan and Ryan Knier for 
technical support.
This work was supported by MH084315 to A.J.S. NRF–2013R1A1A1006766 and NRF–2013R1A3A1072570 to 
Y.–S.L, R37 CA49132 to B.G.N, MEST–2012–0005751 to H.K.K. B.G.N. is also a Canada Research Chair, Tier 1, 
and work in his lab is partially supported by the Ontario Ministry of Health and Long Term Care and the Princess 
Margaret Cancer Foundation.
References
1. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu 
Rev Genomics Hum Genet. 2005; 6:45–68. [PubMed: 16124853] 
2. Romano AA, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. 
Pediatrics. 2010; 126:746–759. [PubMed: 20876176] 
3. Lee DA, Portnoy S, Hill P, Gillberg C, Patton MA. Psychological profile of children with Noonan 
syndrome. Dev Med Child Neurol. 2005; 47:35–38. [PubMed: 15686287] 
4. van der Burgt I, et al. Patterns of cognitive functioning in school-aged children with Noonan 
syndrome associated with variability in phenotypic expression. J Pediatr. 1999; 135:707–713. 
[PubMed: 10586173] 
5. Cesarini L, et al. Cognitive profile of disorders associated with dysregulation of the RAS/MAPK 
signaling cascade. Am J Med Genet A. 2009; 149A:140–146. [PubMed: 19133693] 
6. Pierpont EI, et al. Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain 
Behav. 2009; 8:275–282. [PubMed: 19077116] 
7. Verhoeven W, Wingbermuhle E, Egger J, Van der Burgt I, Tuinier S. Noonan syndrome: 
psychological and psychiatric aspects. Am J Med Genet A. 2008; 146A:191–196. [PubMed: 
18080322] 
8. Alfieri P, et al. Long term memory profile of disorders associated with dysregulation of the RAS-
MAPK signaling cascade. Behav Genet. 2011; 41:423–429. [PubMed: 21274610] 
9. Pierpont EI, Tworog-Dube E, Roberts AE. Learning and memory in children with Noonan 
syndrome. Am J Med Genet A. 2013; 161:2250–2257. [PubMed: 23918208] 
10. Zenker M. Clinical manifestations of mutations in RAS and related intracellular signal transduction 
factors. Curr Opin Pediatr. 2011; 23:443–451. [PubMed: 21750428] 
11. Neel BG, Gu H, Pao L. The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell 
signaling. Trends Biochem Sci. 2003; 28:284–293. [PubMed: 12826400] 
12. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving 
synaptic plasticity and memory. Journal of neurochemistry. 2001; 76:1–10. [PubMed: 11145972] 
13. Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndrome-associated SHP2/PTPN11 mutants 
cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum 
Mutat. 2004; 23:267–277. [PubMed: 14974085] 
14. Araki T, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent 
effects of Ptpn11 mutation. Nat Med. 2004; 10:849–857. [PubMed: 15273746] 
15. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of 
Shp2 mutants. Implications for disease phenotypes. The Journal of biological chemistry. 2005; 
280:30984–30993. [PubMed: 15987685] 
16. Araki T, et al. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to 
enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A. 2009; 106:4736–
4741. [PubMed: 19251646] 
17. Morris RG, Garrud P, Rawlins JN, O’Keefe J. Place navigation impaired in rats with hippocampal 
lesions. Nature. 1982; 297:681–683. [PubMed: 7088155] 
Lee et al. Page 14
Nat Neurosci. Author manuscript; available in PMC 2016 January 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
18. Tartaglia M, et al. Diversity and functional consequences of germline and somatic PTPN11 
mutations in human disease. American journal of human genetics. 2006; 78:279–290. [PubMed: 
16358218] 
19. Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci. 
2009; 10:126–140. [PubMed: 19153576] 
20. Gauthier AS, et al. Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan 
syndrome. Neuron. 2007; 54:245–262. [PubMed: 17442246] 
21. Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R. Ras and Rap control AMPA receptor trafficking 
during synaptic plasticity. Cell. 2002; 110:443–455. [PubMed: 12202034] 
22. Li W, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention 
deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005; 15:1961–1967. [PubMed: 
16271875] 
23. Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the 
growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun. 1991; 3:141–
147. [PubMed: 2043425] 
24. Mailman T, Hariharan M, Karten B. Inhibition of neuronal cholesterol biosynthesis with lovastatin 
leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. 
Journal of neurochemistry. 2011; 119:1002–1015. [PubMed: 21899539] 
25. Lee SH, et al. Synapses are regulated by the cytoplasmic tyrosine kinase Fer in a pathway mediated 
by p120catenin, Fer, SHP-2, and beta-catenin. J Cell Biol. 2008; 183:893–908. [PubMed: 
19047464] 
26. Pagani MR, Oishi K, Gelb BD, Zhong Y. The phosphatase SHP2 regulates the spacing effect for 
long-term memory induction. Cell. 2009; 139:186–198. [PubMed: 19804763] 
27. Rumbaugh G, Adams JP, Kim JH, Huganir RL. SynGAP regulates synaptic strength and mitogen-
activated protein kinases in cultured neurons. Proc Natl Acad Sci U S A. 2006; 103:4344–4351. 
[PubMed: 16537406] 
28. Stornetta RL, Zhu JJ. Ras and Rap signaling in synaptic plasticity and mental disorders. The 
Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry. 2011; 17:54–
78.
29. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway 
dysregulation. Curr Opin Genet Dev. 2009; 19:230–236. [PubMed: 19467855] 
30. Shilyansky C, Lee YS, Silva AJ. Molecular and cellular mechanisms of learning disabilities: a 
focus on NF1. Annu Rev Neurosci. 2010; 33:221–243. [PubMed: 20345245] 
31. Shilyansky C, et al. Neurofibromin regulates corticostriatal inhibitory networks during working 
memory performance. Proc Natl Acad Sci U S A. 2010; 107:13141–13146. [PubMed: 20624961] 
32. Cui Y, et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. 
Cell. 2008; 135:549–560. [PubMed: 18984165] 
33. Costa RM, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 
1. Nature. 2002; 415:526–530. [PubMed: 11793011] 
34. Zolotukhin S, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-
associated viral vectors. Methods. 2002; 28:158–167. [PubMed: 12413414] 
35. Hajos N, Nusser Z, Rancz EA, Freund TF, Mody I. Cell type- and synapse-specific variability in 
synaptic GABAA receptor occupancy. Eur J Neurosci. 2000; 12:810–818. [PubMed: 10762310] 
Lee et al. Page 15
Nat Neurosci. Author manuscript; available in PMC 2016 January 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. NS mice show spatial memory deficits
a. Escape latencies of Ptpn11N308D/+ (n = 9) and WT littermates (n = 11) were not different 
in the hidden platform version of the water maze.
b. Ptpn11N308D/+ and WT littermates selectively searched in the target quadrant in a probe 
trial given after 3 days of training (Ptpn11N308D/+, n = 9 mice, One-way ANOVA, F3, 32 = 
13.82, *** P < 0.001; WT, n = 11 mice, One-way ANOVA, F3, 40 = 48.48, *** P < 0.001). 
However, Ptpn11N308D/+ mice spent significantly less time in the target quadrant than WT 
mice. Two-way ANOVA for quadrant occupancy with genotype as between-subjects factor 
and pool quadrant as within-subjects factor, genotype x pool quadrant interaction: F3,54 = 
4.091, * P < 0.05. Pool quadrants; target (T), adjacent right (AR), opposite (O), and adjacent 
left (AL) quadrant.
c. Ptpn11D61G/+ mutants (n = 10) showed significantly longer latency to the platform during 
training compared with WT controls (n = 15) in the hidden–platform version of the water 
maze.
d. Quadrant occupancy for the probe trial conducted after 3 days of training reveals that 
Ptpn11D61G/+ mice (n=10) did not show preference for the target quadrant, but their WT 
littermates (n=15) did. In addition, Ptpn11D61G/+ mice spent significantly less time in the 
target quadrant than did WT mice (Ptpn11D61G/+, 27.44 ± 2.04 %; WT, 37.14 ± 2.09, ** P < 
0.01; unpaired two-tailed t-test). Two-way ANOVA for quadrant occupancy with genotype 
as between-subjects factor and pool quadrant as within-subjects factor, genotype x pool 
quadrant interaction: F3, 69 = 2.884, * P < 0.05. n.s., not significant (P > 0.05).
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Figure 2. NS mice show LTP deficits
a. LTP induced by a 5 TBS was reduced significantly in hippocampal slices from 
Ptpn11N308D/+ mice compared with their WT littermates (WT, n = 6 slices from 6 mice; 
Ptpn11N308D/+, n = 6 slices from 6 mice; Repeated-measures ANOVA: F1, 10 = 7.893, P < 
0.05).
b. LTP induced by a 5 TBS protocol was reduced in hippocampal slices from Ptpn11D61G/+ 
mice compared with those from WT mice (WT, n = 7 slices from 7 mice; Ptpn11D61G/+, n = 
7 slices from 6 mice; Repeated-measures ANOVA: F1,12 = 5.828, P < 0.05). fEPSP slopes 
normalized to the average baseline response before LTP induction (at time 0) are plotted in 
2-min blocks. Sample traces show responses during baseline (gray) and the last 10 min 
(black) of the recording (average of ten recording traces). Scale: vertical bar, 0.5 mV; 
horizontal bar, 4 ms. Error bars represent s.e.m.
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Figure 3. PTPN11D61G overexpression induces learning and memory and LTP deficits that can 
be reversed by MEK inhibition
a. AAV–PTPN11D61G infection results in overexpression of SHP2D61G. Anti–SHP2 
immunohistochemistry shows robust overexpression of SHP2 in the hippocampus of AAV–
PTPN11D61G–infused brains (left) compared with AAV–GFP infused brains (right). Full-
length blots/gels are presented in Supplementary Figure 11.
b. PTPN11D61G overexpression increases basal Erk activity (phospho–Erk level) and 
prevents further Erk activation in response to TBS. Left, Representative immunoblot 
showing p–Erk (upper) and total Erk (lower) in PTPN11D61G–expressing slices and GFP–
expressing slices. Slices were prepared 1 h after TBS. Right, Bar graph displays normalized 
p–Erk levels (mean ± s.e.m.). CTL, control without TBS.
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c. MEK inhibitor SL327 reverses spatial memory deficits in PTPN11D61G–overexpressing 
mice in the Morris water maze. Quadrant occupancy analysis for the probe trial reveals that 
PTPN11D61G/veh mice showed no preference for the target quadrant (target vs. other 
quadrants, Dunnett’s Multiple Comparison Test after one-way ANOVA, P > 0.05). 
PTPN11D61G/veh mice also spent significantly less time in the target quadrant compared 
with GFP/veh mice. SL327 treatment significantly increased the time spent in the target 
quadrant in PTPN11D61G-expressing mice compared with vehicle-treated PTPN11D61G 
mice (PTPN11D61G/SL327, 37.25 ± 3.50 %, n=10, unpaired two-tailed t-test, t = 2.335, * P 
< 0.05).
d. PTPN11D61G overexpression in the hippocampus impairs memory in the object–place 
recognition test. Control mice expressing WT PTPN11 spent significantly more time 
exploring the object in the new place than exploring the object in the old place during the 
test session 24 h after training. However, PTPN11D61G–overexpressing mice did not show 
preference for the object in the new place.
e. MEK inhibitor SL327 rescues memory deficits in object–place recognition test caused by 
PTPN11D61G overexpression. When SL327 (32 mg/kg) was injected 30 min before training 
in the object-place recognition test, both PTPN11– and PTPN11D61G–expressing mice spent 
significantly more time exploring the object in the new place than exploring the object in the 
old place during the test session 24 h after training.
f. and g. MEK inhibitor SL327 reverses LTP deficits caused by PTPN11D61G 
overexpression. f. PTPN11D61G overexpression significantly impaired 5 TBS–induced LTP, 
and bath application of SL327 reversed the deficit (Repeated-measures ANOVA, F3, 72 = 
140.2, P < 0.0001). SL327 (1 μM) was applied for 1 h before LTP induction, and then 
maintained in the bath throughout recording. g. Average % fEPSP changes (last 10 minutes 
of recording) shows a significant LTP deficit in the vehicle-treated PTPN11D61G group 
compared with the vehicle-treated GFP group (GFP/veh, 154.8 ± 4.18 %, n=7; 
PTPN11D61G/veh, 131.9 ± 4.38, n=10; unpaired two-tailed t-test, t = 3.625, ** P < 0.01) and 
significant reversal by SL327 treatment (PTPN11D61G/SL327, 146.1 ± 4.36 %, n=10; 
unpaired two-tailed t-test, t = 2.309, * P < 0.05). SL327 did not affect LTP in the GFP 
group (GFP/SL327, 146.2 ± 4.37 %, n=7; unpaired two-tailed t-test, t = 1.414, P = 0.183).
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Figure 4. PTPN11D61G overexpression enhances excitatory synaptic function through increased 
Ras-Erk signaling
a. AMPA receptor-mediated currents were measured at the peak of the currents at − 65 mV, 
and NMDA currents were measured 50 ms after onset at + 40 mV. The average of 15 traces 
is shown. Scale, 100 pA and 40 ms.
b. Group data showing the increased AMPA:NMDA current ratio in AAV–PTPN11D61G 
mice compared with AAV-GFP mice. SL327 treatment (1 μM, 1 h) significantly reversed 
the AMPA:NMDA current ratio in the PTPN11D61G group without affecting GFP–
expressing mice. Two-way ANOVA, interaction between viral treatment and drug, F1, 31 = 
10.53, ** P < 0.01. Bonferroni post-test reveals significant effect of SL327 treatment only 
on PTPN11D61G group (** P < 0.01).
c. Paired-pulse facilitation ratio is unaffected by PTPN11D61G. There was no significant 
difference at 25 ms or 50 ms intervals between the two groups.
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d. PTPN11D61G overexpression increases excitatory synaptic function. Left, Representative 
traces of mEPSC recordings from GFP or PTPN11D61G–expressing hippocampus. Middle, 
mEPSC frequency was increased in AAV–PTPN11D61G–transfected mice compared with 
AAV–GFP mice, and was reversed by SL327 (1 μM) treatment without affecting on the 
AAV–GFP group. Two-way ANOVA with viral treatment as between-subjects factor, F1, 30 
= 10.31, ** P < 0.01. Right, mEPSC amplitudes were not significantly different among 
groups. Two-way ANOVA with viral treatment as between-subjects factor, F1, 30 = 0.470, P 
= 0.498. Scale, 20 pA and 200 ms.
e. Excitatory synaptic function is increased in Ptpn11D61G/+ mutant mice and reversed by 
SL327 treatment. Left, Representative traces of mEPSC recordings from WT or 
Ptpn11D61G/+ mice. Middle, mEPSC frequency was increased in Ptpn11D61G/+ mice 
compared with WT littermates, and was reversed by SL327 (1 μM) treatment. Two-way 
ANOVA with genotype as between-subjects factor, F1, 33 = 5.914, * P < 0.05. Right, 
mEPSC amplitudes were not significantly different among groups. Two-way ANOVA with 
genotype as between-subjects factor, F1, 33 = 0.418, P = 0.839. Scale, 20 pA and 200 ms.
f. and g. mIPSC was not changed in either AAV–PTPN11D61G-transfected mice or 
Ptpn11D61G/+ mutants. f. Representative traces of mIPSC recordings from GFP or 
PTPN11D61G–expressing hippocampus. g. Representative traces of mIPSC recordings from 
Ptpn11D61G/+ mutant mice or WT littermates. Scale, 20 pA and 1 s.
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Figure 5. PTPN11D61G overexpression increases surface AMPA receptor expression
a. and b. Representative images of surface GluA1 staining in cultured neurons. GFP alone 
(a) or PTPN11D61G and GFP (b) were co–expressed using a bicistronic Sindbis viral vector 
in cultured hippocampal neurons (DIV21). Scale, 20μm.
c. Representative images of western blotting of total and biotinylated surface proteins. 
Cadherin and Rab-4 were used as markers for surface and cytosol expression, respectively. 
Full-length blots/gels are presented in Supplementary Figure 11.
d. Surface expression of GluA1 was significantly increased in PTPN11D61G expressing 
neurons compared to WT PTPN11 expressing neurons, while the total expression level of 
GluA1 did not differ between WT PTPN11 and PTPN11D61G transfected neurons.
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Figure 6. Lovastatin treatment reverses spatial learning and memory and LTP deficits in 
Ptpn11D61G/+ mice
a. Lovastatin treatment reverses increased Erk activation in hippocampi from Ptpn11D61G/+ 
mice. Left, Representative immunoblot showing p-Erk (upper) and total Erk (lower) levels in 
WT and Ptpn11D61G/+ mutant mice. Hippocampi were dissected 6 h after the 4th day of 
lovastatin injection (subcutaneous (s.c.) injections, 10 mg/kg). Full-length blots/gels are 
presented in Supplementary Figure 11. Right, Bar graph displaying normalized p-Erk levels 
(mean ± s.e.m.).
b. Vehicle-treated Ptpn11D61G/+ mutant mice showed significantly longer latency to the 
hidden platform during training sessions compared with vehicle-treated WT mice. 
Lovastatin-treated Ptpn11D61G/+ mice showed comparable latency to WT mice.
c. Lovastatin treatment did not improve swimming speed.
d and e. Lovastatin treatment (10 mg/kg) reverses spatial memory deficits in Ptpn11D61G/+ 
mice at a concentration that does not affect WT controls. d. Quadrant occupancy analysis for 
the probe trail reveals that Ptpn11D61G/+ mice with vehicle treatment (Ptpn11D61G/+/veh) 
showed no preference for the target quadrant (target vs. other quadrants, Dunnett’s Multiple 
Comparison Test after one-way ANOVA, P > 0.05). By contrast, the Ptpn11D61G/+/Lova 
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group selectively searched for the target quadrant, suggesting that lovastatin treatment 
reversed the spatial memory deficit in Ptpn11D61G/+ mice (target vs. other quadrants, 
Dunnett’s Multiple Comparison Test after one-way ANOVA, *** P < 0.0001). The 
Ptpn11D61G/+/Lova group also spent significantly more time in the target quadrant 
compared with Ptpn11D61G/+/veh mice. e. Proximity analysis reveals that the spatial 
memory deficit in Ptpn11D61G/+ mice can be reversed by lovastatin treatment.
f ang g. Lovastatin treatment reverses LTP deficits in Ptpn11D61G/+ mice at concentrations 
that do not affect WT littermates. f. Ptpn11D61G/+ mice showed a deficit in 5 TBS-induced 
LTP that was reversed by systemic administration of lovastatin (Repeated-measures 
ANOVA, F3, 96 = 14.38, P < 0.0001). g. Average % fEPSP changes (last 10 minutes of 
recordings) show that lovastatin treatment significantly rescued the LTP deficit in 
Ptpn11D61G/+ mice (WT/veh, 159.6 ± 5.33 %, n=7; WT/Lova, 150.7 ± 5.49 %, n=6; 
Ptpn11D61G/+/veh, 131.7 ± 2.31 %, n=9; Ptpn11D61G/+/Lova, 154.2 ± 6.88 %, n=7; unpaired 
two-tailed t-test, ** P < 0.01, *** P < 0.001).
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